This week, STAT held a webinar entitled "What to Expect in Biotech 2018." The broadcast was hosted by Adam Feurstein, a senior biotech reporter, and Damian Garde, a national biotech reporter. The goal of the webinar was to provide a framework of the themes that are likely to shape the biotech sector in the coming year, as well to provide a look at biotech stocks in 2018.
This week, STAT held a webinar entitled “What to Expect in Biotech in 2018.” The broadcast was hosted by Adam Feurstein, a senior biotech reporter, and Damian Garde, a national biotech reporter. The goal of the webinar was to provide a framework of the themes that are likely to shape the biotech sector in the coming year, as well to provide a look at biotech stocks in 2018.
Garde highlighted the strides that both FDA Commissioner Scott Gottlieb, MD, and the FDA itself made in 2017 to expedite drug approvals and provide a more efficient, streamlined drug development process. Garde noted that it will be important to watch certain drugs after they’ve received expedited approval to make sure that drug efficacy or safety is still maintained through this quicker process.
Feurstein discussed potential upcoming FDA drug approvals throughout the year that could affect the biotech market, including:
According to a J.P. Morgan poll, 60% of investor respondents expect the biotech sector to outperform the broader market in 2018, and 84% expect an increase in mergers and acquisitions.
Presenters briefly mentioned biosimilars in the broadcast, stating that they’re here to stay, and companies that are making reference products will have to become innovative to keep up with the expected cost-savings from biosimilars, once more come to market.
As far as how the new tax reform bill could affect biotech companies, STAT believes that the increase in cash savings could result in either more mergers and acquisitions, or stock share buybacks later this year. According to the webcast, Amgen, Gilead Sciences, and Merck all hold more than $20 billion overseas.
The presentation closed with some drug launches and clinical trials to watch this year:
Drug launches:
Clinical Trials:
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.